Water Vapor Ablation for Grade Group 3 Prostate Cancer (VAPOR 3)

Vanquish® Water Vapor Ablation for Grade Group 3 PrOstate CanceR: A Multicenter Single Arm Study

The goal of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation System ("Vanquish") in participants with Grade Group 3 (GG3) intermediate-risk prostate cancer.

Participants will undergo therapy with the Vanquish System and complete follow up visits at 7 days, 6 weeks, 6 months, 12 months, 18 months, and 24 months.

Study Overview

• Status: Not yet recruiting
• Conditions: Prostate Cancer
• Intervention / Treatment: Device: Water Vapor Ablation

• Study Type: Interventional
• Enrollment (Estimated): 120
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Rachael Krzmarzick; Phone Number: 763-607-5997; Email: rkrzmarzick@francismedical.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participant has been diagnosed with Grade Group 3 (GG3) intermediate-risk prostate cancer.
• ≤20 ng/ml prostate specific antigen (PSA).
• Prostate volume of 20-80cc per Central Imaging read.
• ≥50 years of age; with life expectancy of ≥10 years.
• Clinical cancer stage less than or equal to T2c (tumor may involve both sides of the prostate but without evidence that tumor extends outside of the prostate and with no cancer cells found in nearby lymph nodes) evaluated by prostate specific membrane antigen positron emission tomography (PSMA PET) scan.

• Within 6 months prior to signing consent have had a multiparametric MRI (mpMRI).

  a.) mpMRI results must show localized disease meaning a single MRI region of suspicion (PI-RADS lesion volume ≤2.25cc with a maximum lesion diameter <17mm as measured by diffusion weighted imaging (DWI) determined by Central Imaging).

• Within 6 months prior to signing consent, have undergone a multiparametric MRI software guided fusion biopsy of the prostate (transrectal or transperineal).

  1. Minimum of 2 targeted cores from a single ROI identified by Central Imaging review, and at least one core confirming GG3 disease on biopsy (lesion may cross the midline); Gleason Grade Group determined by highest Gleason score of the targeted core.
  2. GG1 cores from anywhere in the prostate are acceptable.
  3. Less than 50% of systematic biopsy cores are positive for GG1 disease. For the <50% calculation, all positive cores located in the target, are counted as "one core."
  4. All positive GG2 or GG3 cores must be located in the lesion, or immediately adjacent to the lesion, as determined by the fusion system's tracking, mapping and imaging documentation features.
  5. Additional MRI regions of suspicion that are Central Imaging confirmed PI-RADS ≤3 that are negative on biopsy or GG1 are acceptable.

• Within 6 months prior to signing consent have had a PSMA-PET scan.

  1. PSMA-PET scan results show no suspicion of metastasis as determined by site read.
  2. Per Central Imaging, PSMA-PET scan prostate results are concordant with mpMRI results
  3. If PSMA-PET scan indicates an additional area of suspicion from the planned treatment area, a targeted repeat biopsy is required to rule out ≥ GG2.
• Participant is willing and able to adhere to specific protocol visits and required testing, including completion of all questionnaires, throughout study.
• Participant is geographically stable and near the site or able and willing to travel back to site for follow-up visits.
• Participant is able and willing to provide written consent to participate in the study.

Exclusion Criteria:

• MRI evidence of extracapsular extension of cancer (MRI read as capsular invasion, bulge, or frank ECE) as determined by Central Imaging.
• Any additional Central Imaging confirmed PI-RADS 4 or 5 suspicious lesions.
• Participants with ≥GG4 cores anywhere in the prostate.
• Participants with GG2 or GG3 cores outside the region of interest.
• Contraindications per the Vanquish Instructions for Use.
• Any previous treatment for prostate cancer or any prior surgery, intervention, or minimally invasive therapy (MIST) for the prostate or bladder neck, including but not limited to Vanquish therapy, TUIP, TURP, Aquablation, Green Light, Rezūm, Prostatic Urethral Lift, iTind, Prostatic Arterial Embolization, or microwave therapy.

• Currently taking medications that have hormonal effects on the prostate or PSA, such as:

  1. 5 alpha reductase inhibitors, if on for < 6 months (6-month washout required if participant is able and willing to stop medication),
  2. Androgen blockers,
  3. Luteinizing hormone-releasing hormone agonists or antagonists within the past 12 months,
  4. or Testosterone supplementation, if on for < 3 months (3-month washout required if participant is able and willing to stop medication)
  5. A participant on benign prostatic hyperplasia medication which does not affect the PSA can be included.
• Treated within the past 5 years for a lower and/or upper urinary tract malignancy.
• Any cognitive or psychiatric condition that interferes with or precludes direct and accurate communication with the study Investigator regarding the study or affects the ability to complete the study quality of life (QOL) questionnaires.
• Participant currently participating in other prostate tissue and/or cancer study unless approved by Sponsor in writing.
• Participant is considered vulnerable, such as incarcerated or cognitively impaired.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Vanquish System Therapy	Device: Water Vapor Ablation; Water vapor ablation delivered transurethrally in patients with Grade Group 3 (GG3) intermediate risk prostate cancer.; Other Names: Vanquish System Therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ablative Efficacy 6-Months Post Ablation	Ablative efficacy after one or two ablations indicating <GG2 cancer in the region of the prostate targeted for Vanquish therapy and evaluated at 6 months post ablation.	6 months post procedure.
Rate of Serious Adverse Events Through 6-Months	Rate of serious adverse events through 6-months classified per Clavien-Dindo and assessed as related to the Vanquish procedure and/or device. Clavien-Dindo Classifications; Grade I: Any deviation from the normal postoperative course without the need for pharmacological treatment, surgical, endoscopic, or radiological interventions.; Grade II: Requires pharmacological treatment with drugs other than those allowed for Grade I complications.; Grade III: Complications requiring surgical intervention (IIIa: laparoscopic, IIIb: open).; Grade IV: Life-threatening complications (IVa: single organ failure, IVb: multi-organ failure).; Grade V: Death of a patient.	From the start of the Vanquish procedure through 6-months post procedure.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of Serious Adverse Events Through 24-Months	Rate of serious adverse events through 24-months classified per Clavien-Dindo and assessed as related to the Vanquish procedure and/or device. Clavien-Dindo Classifications; Grade I: Any deviation from the normal postoperative course without the need for pharmacological treatment, surgical, endoscopic, or radiological interventions.; Grade II: Requires pharmacological treatment with drugs other than those allowed for Grade I complications.; Grade III: Complications requiring surgical intervention (IIIa: laparoscopic, IIIb: open).; Grade IV: Life-threatening complications (IVa: single organ failure, IVb: multi-organ failure).; Grade V: Death of a patient.	From the start of the Vanquish procedure through 24-months post procedure.

Collaborators and Investigators

• Sponsor: Francis Medical Inc.

Study record dates

Study Major Dates

• Study Start (Estimated): August 31, 2026
• Primary Completion (Estimated): August 1, 2028
• Study Completion (Estimated): September 1, 2028

Study Registration Dates

• First Submitted: June 11, 2026
• First Submitted That Met QC Criteria: June 11, 2026
• First Posted (Actual): June 16, 2026

Study Record Updates

• Last Update Posted (Actual): August 11, 2026
• Last Update Submitted That Met QC Criteria: August 7, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: Prostate Cancer; Ablation; Vapor; Water Vapor; Grade Group 3
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Prostatic Neoplasms
• Other Study ID Numbers: 5700-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No